1 published article · Updated continuously
9 trials tracked for Ischemic cardiomyopathy: 1 in phase 3 or 4 and 1 with published results. The most-cited published study has 83 citations.
Showing the 9 most-cited and recently-updated of 9 trials. Browse the full registry →
Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.
In patients with ischemic cardiomyopathy, Ranolazine was evaluated for its impact on ventricular arrhythmias. While there was no statistically significant difference in the total number of patients experiencing ventricular tachycardia (VT), ventricular fibrillation (VF), or death (p=0.117), or those requiring ICD shock for these events (p=0.891), Ranolazine was associated with a significant reduction in the number of recurrent episodes of VT or VF requiring antitachycardia pacing (ATP) or ICD shock therapies (p=0.028) 1.
AI synthesis of 2 cited trials, updated Sep 7, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.
